Day: December 3, 2024

LIVERMORE, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) — Advent Technologies Holdings, Inc. (NASDAQ: ADN) (“Advent” or the “Company”), an innovation-driven leader in the fuel cell and hydrogen technology space, is pleased to announce that its H2VE proposal has passed the evaluation process. Advent’s technical team of Anastasia Koutsomitopoulou, Olga Bereketidou, and Nora Gourdoupi made this achievement possible. This grant of €115,437 will be used towards summer school programs, study visits, presentations, workshops, and networking events in the Western Macedonia Region. The program will last 48 months and was submitted under the call, ERASMUS-EDU-2024-PEX-COVE (Centres of Vocational Excellence). Konstantinos Ferderigos, Advent’s General Manager in Greece, commented, “We are very pleased with this grant award....

KISSIMMEE, Fla., Dec. 03, 2024 (GLOBE NEWSWIRE) — ECD Automotive Design, Inc. (Nasdaq: ECDA), (“ECD” or the “Company”), an industry leader in building and selling restored, modified and electrified Land Rover Defenders, Jaguar E-Types, Ford Mustangs, and Toyota FJs is set to debut its first retail presence through a strategic relationship with One Drivers Club in West Palm Beach. This strategic collaboration positions ECD as a new, prestigious retailer at One Drivers Club’s luxury automotive destination, marking a significant expansion for ECD into retail and physical experiences for both companies. The 4,800-square-foot space near “Billionaire’s Row” will serve as both a shared clubhouse, sales showroom and an immersive design center. This showroom will allow ECD clients to personalize custom builds across ECD’s lineup—from Land...

MANITOWOC, Wis., Dec. 03, 2024 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, electric vehicle (EV) charging stations, and maintenance service solutions, announced today it has been selected to provide lighting retrofit solutions for a North American Building Products distributor covering over 400 locations. The project will commence in Orion’s Q3 FY25 and is anticipated to continue for several years. Orion values the total opportunity as $12 – $18M with about $1M anticipated for FY25. The project encompasses site visits, lighting audits, fixture manufacturing, project management, and the installation and commissioning of industry-leading LED lighting systems across the customer’s national store footprint. Orion will provide a combination of LED...

REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced that it has entered into a definitive agreement for the purchase and sale of 472,668 of the Company’s American Depositary Shares (“ADSs”), each ADS representing 200 ordinary shares, at a purchase price of $6.00 per ADS, in a registered direct offering. The closing of the offering is expected to occur on or about December 4, 2024, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be approximately $2.8 million,...

FREDERICK, Md., Dec. 03, 2024 (GLOBE NEWSWIRE) — BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL, a developer of medical technology products, today announces that Sree Koneru, PhD, will join its Board of Directors, effective December 3, 2024. Upon Dr. Koneru’s appointment, the Board will consist of three members, including Kelly Whelan, President of BioElectronics, and its Chairman, Richard Staelin, PhD. “We are honored to welcome Sree Koneru to the Board. Sree brings a rich depth of experience in medical device development.  We welcome his insight as we execute our strategy,” said Kelly Whelan, President of BioElectronics Corporation.  “I am honored to join the Board of Directors at BioElectronics, a company at the forefront of innovations in neuromodulation,” said Sree Koneru, “The...

First three Single Ascending Dose cohorts demonstrated no treatment related adverse events Carlsbad, CA, Dec. 03, 2024 (GLOBE NEWSWIRE) — Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced preliminary results from its first three single ascending dose (SAD) cohorts in its ongoing Phase 1 human clinical study for PALI-2108 for the treatment of Ulcerative Colitis (UC). The ongoing Phase 1 study is evaluating PALI-2108 in a single-center, double-blind, placebo-controlled study focused on safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy volunteers, alongside an open-label study involving a patient cohort with UC. Preliminary...

21Shares will welcome a new suite of executives to drive growth for the firm Co-Founders Hany Rashwan and Ophelia Snyder will become co-chairs of 21Shares, while dedicating their executive time and attention to 21.co Technologies ZURICH, 3 December 2024 – 21.co today announced the company’s new operating structure to prepare for a new phase of growth in digital assets and blockchain technology. 21.co’s operating structure will transition from one fully integrated business to two, separated core business units – 21Shares and 21.co Technologies. 21.co remains the Holding Company of both 21Shares and 21.co Technologies. The separation of 21Shares and 21.co Technologies allows each entity to focus on its strengths and to more easily meet their individual business goals. 21Shares will remain laser focused on asset management and bringing the...